Cargando…

Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer

BACKGROUND: The low probability of curing high-risk prostate cancer (PC) with local therapy suggests the need to study modality of therapeutic approaches. To this end, a prospective phase II trial of neoadjuvant docetaxel (D) and complete androgen blockade (CAB) was carried out in high-risk PC patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mellado, B, Font, A, Alcaraz, A, Aparicio, L A, Veiga, F J G, Areal, J, Gallardo, E, Hannaoui, N, Lorenzo, J R M, Sousa, A, Fernandez, P L, Gascon, P
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768456/ https://www.ncbi.nlm.nih.gov/pubmed/19755998 http://dx.doi.org/10.1038/sj.bjc.6605320

Ejemplares similares

Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer
por: Thalgott, Mark, et al.
Publicado: (2014)

Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer
por: Narita, Shintaro, et al.
Publicado: (2012)

Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study
por: Carles, J, et al.
Publicado: (2007)

Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel
por: Jiménez, Natalia, et al.
Publicado: (2022)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Exceptional pathologic complete response achieved with androgen deprivation and docetaxel therapy in Gleason 10 prostate cancer
por: Vaishampayan, Ulka, et al.
Publicado: (2019)

Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer
por: Mout, Lisanne, et al.
Publicado: (2020)

Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate
por: Amat, S, et al.
Publicado: (2003)

Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
por: Lin, Binwei, et al.
Publicado: (2023)

Histological complete response to a combined docetaxel/cisplatin/fluorouracil neoadjuvant chemotherapy for T4 stage gastric adenocarcinoma
por: Guo, Ming gao, et al.
Publicado: (2014)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
por: Li, Jian-Ri, et al.
Publicado: (2017)

Maximal androgen blockade for the treatment of metastatic prostate cancer—a systematic review
por: Lukka, H., et al.
Publicado: (2006)

Maximal androgen blockade for advanced prostate cancer
por: Mukha, Rajiv Paul, et al.
Publicado: (2010)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Androgen deprivation therapy plus abiraterone or docetaxel as neoadjuvant therapy for very-high-risk prostate cancer: a pooled analysis of two phase II trials
por: Zhuang, Junlong, et al.
Publicado: (2023)

Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2018)

Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis
por: Maiorano, B.A., et al.
Publicado: (2022)

Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression
por: Jethwa, Krishan R., et al.
Publicado: (2016)

The efficacy and safety of docetaxel plus thalidomide vs. docetaxel alone in patients with androgen-independent prostate cancer: a systematic review
por: Chen, Long, et al.
Publicado: (2014)

A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer
por: Fujishima, Hajime, et al.
Publicado: (2017)

Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model
por: Mirjolet, Céline, et al.
Publicado: (2017)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
por: Li, Qi, et al.
Publicado: (2019)

Genetic variations predicting progression with docetaxel and novel androgen‐receptor pathway inhibitors
por: Shiota, Masaki, et al.
Publicado: (2023)

Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Ryan, Charles J, et al.
Publicado: (2019)

Role of maximum androgen blockade in advanced prostate cancer
por: Ayyathurai, Rajinikanth, et al.
Publicado: (2009)

Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response
por: Thompson, Kevin J, et al.
Publicado: (2022)

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
por: Vieira, Cláudia, et al.
Publicado: (2022)

Orchiectomy or androgen receptor blockade attenuates baroreflex-mediated bradycardia in conscious rats
por: Ward, Gregg R, et al.
Publicado: (2006)

Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer
por: Walker, Leslie G, et al.
Publicado: (2011)

Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer
por: Wang, Ling-Cheng, et al.
Publicado: (2020)

Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer
por: Fu, Jin Ye, et al.
Publicado: (2022)

SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
por: Vasey, P A, et al.
Publicado: (2006)

Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension (NDLS) versus Conventional Docetaxel as Neoadjuvant and Adjuvant Therapy for Primary Operable Breast Cancer
por: Badiginchala, Revathi, et al.
Publicado: (2023)

Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study
por: Awada, A, et al.
Publicado: (2008)

Complete androgen blockade vs. medical castration alone as adjuvant androgen deprivation therapy for prostate cancer patients following radical prostatectomy: a retrospective cohort study
por: Jin, Di, et al.
Publicado: (2022)

Long-Term Outcomes of a Phase I Trial of Weekly Docetaxel, Total Androgen Blockade, and Image Guided Intensity Modulated Radiation Therapy for Localized High-Risk Prostate Adenocarcinoma
por: McVorran, Shauna, et al.
Publicado: (2022)

Predictive factors of neoadjuvant immune checkpoint blockade in melanoma
por: Sarver, Melissa, et al.
Publicado: (2021)

Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade
por: Lassche, Gerben, et al.
Publicado: (2021)

SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer
por: Clamp, A R, et al.
Publicado: (2006)

Quality of Life During and After Completion of Neoadjuvant Chemoradiotherapy for Esophageal and Junctional Cancer
por: Noordman, B. J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_944nsi8eu08vsdagm047ed23p4